Float Short %

8.09

Margin Of Safety %

Put/Call OI Ratio

0.21

EPS Next Q Diff

0.03

EPS Last/This Y

1.39

EPS This/Next Y

0.92

Price

96.15

Target Price

112.5

Analyst Recom

1.13

Performance Q

52.68

Relative Volume

0.75

Beta

2.14

Ticker: RYTM

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	RYTM	97.72	0.88	0.16	8380
2025-08-18	RYTM	98.04	0.37	0.00	7825
2025-08-19	RYTM	97.21	0.31	0.00	8956
2025-08-20	RYTM	98.65	0.31	3.14	8954
2025-08-21	RYTM	101.71	0.31	0.51	8956
2025-08-22	RYTM	103.22	0.31	1.20	8994
2025-08-25	RYTM	99.6	0.31	0.21	9049
2025-08-26	RYTM	101.2	0.30	0.00	9086
2025-08-27	RYTM	102.33	0.28	0.07	9690
2025-08-28	RYTM	104.2	0.28	0.05	9726
2025-08-29	RYTM	103.25	0.27	0.02	9871
2025-09-02	RYTM	104.12	0.26	0.02	10296
2025-09-03	RYTM	101.71	0.23	0.75	11407
2025-09-04	RYTM	104.56	0.23	2.00	11411
2025-09-05	RYTM	102.11	0.23	0.00	11411
2025-09-08	RYTM	99.78	0.20	0.05	12864
2025-09-09	RYTM	101.46	0.21	0.22	13558
2025-09-10	RYTM	100.27	0.21	0.47	13577
2025-09-11	RYTM	97.92	0.21	1.11	13575
2025-09-12	RYTM	96.2	0.21	0.20	13624
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	RYTM	97.72	3.4	-	-2.95
2025-08-18	RYTM	98.09	3.4	-	-2.95
2025-08-19	RYTM	97.19	3.4	-	-2.95
2025-08-20	RYTM	98.70	3.4	-	-2.95
2025-08-21	RYTM	101.71	3.4	-	-2.95
2025-08-22	RYTM	103.29	3.4	-	-2.95
2025-08-25	RYTM	99.19	-0.5	-	-2.95
2025-08-26	RYTM	101.20	-0.5	-	-2.95
2025-08-28	RYTM	104.23	-0.5	-	-2.95
2025-08-29	RYTM	103.16	-0.5	-	-2.95
2025-09-02	RYTM	104.18	-0.5	-	-2.95
2025-09-03	RYTM	101.71	-0.5	-	-2.95
2025-09-04	RYTM	104.46	-0.5	-	-2.95
2025-09-05	RYTM	102.12	-0.5	-	-2.95
2025-09-08	RYTM	99.77	-0.5	-	-2.95
2025-09-09	RYTM	101.43	-0.5	-	-2.95
2025-09-10	RYTM	100.25	-0.5	-	-2.95
2025-09-11	RYTM	97.92	-0.5	-	-2.95
2025-09-12	RYTM	96.15	-0.5	-	-2.95
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	RYTM	-6.47	0.49	7.43
2025-08-18	RYTM	-6.47	0.53	7.45
2025-08-19	RYTM	-6.31	0.53	7.35
2025-08-20	RYTM	-6.97	0.53	7.35
2025-08-21	RYTM	-6.97	0.53	7.34
2025-08-22	RYTM	-7.10	0.53	7.34
2025-08-25	RYTM	-7.10	3.27	7.34
2025-08-26	RYTM	-7.17	3.27	7.34
2025-08-27	RYTM	-7.17	3.27	7.60
2025-08-28	RYTM	-7.17	3.27	7.60
2025-08-29	RYTM	-7.17	3.27	7.60
2025-09-02	RYTM	-7.17	3.22	7.60
2025-09-03	RYTM	-7.17	3.22	7.60
2025-09-04	RYTM	-7.47	3.22	7.60
2025-09-05	RYTM	-7.47	3.22	7.60
2025-09-08	RYTM	-7.47	3.21	7.60
2025-09-09	RYTM	-7.47	3.21	7.60
2025-09-10	RYTM	-7.47	3.21	7.60
2025-09-11	RYTM	-7.47	3.21	8.08
2025-09-12	RYTM	-7.47	3.21	8.09
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.75

Avg. EPS Est. Current Quarter

-0.73

Avg. EPS Est. Next Quarter

-0.72

Insider Transactions

-7.47

Institutional Transactions

3.21

Beta

2.14

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

9.7

Max Drawdown 5-Year %

-92.1

Target Price

112.5

P/E

Forward P/E

PEG

P/S

40.89

P/B

P/Free Cash Flow

EPS

-3.02

Average EPS Est. Cur. Y

-2.95

EPS Next Y. (Est.)

-2.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-120.55

Relative Volume

0.75

Return on Equity vs Sector %

-165.9

Return on Equity vs Industry %

-152.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.11

EBIT Estimation

Rhythm Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 283

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.

stock quote shares RYTM – Rhythm Pharmaceuticals Inc. Stock Price stock today

news today RYTM – Rhythm Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RYTM – Rhythm Pharmaceuticals Inc. yahoo finance google finance

stock history RYTM – Rhythm Pharmaceuticals Inc. invest stock market

stock prices RYTM premarket after hours

ticker RYTM fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: RYTM

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y